German Qiagen up on talk of bid by Sanofi-Aventis

Shares in Qiagen rose more than 5 percent on Friday as traders cited market talk that French drug specialist Sanofi-Aventis was considering a bid for the German Biotech. "I've heard talk of a bid of 14.50 euros per share for Qiagen," a Frankfurt-based trader says. A spokesman at Sanofi-Aventis said the company does not comment on market rumours.

German Qiagen up on talk of bid by Sanofi-Aventis - News - CNBC.com

4 comments:

Rocky said...

I appreciate the labour you have put in developing this blog. Nice and informative.

Lindasy Rosenwald said...

Lindsay Rosenwald http://www.lindsay-rosenwald.com/ know more about Dr. Lindsay Rosenwald and achievements facts.

Christian Lange said...

Sanofi-Aventis is a drug development company, and not engaged in the diagnostics market. So this was a canard, I guess...

Market Research Company said...

Very nice article you have written here i like it in fist time. Hope you will post more usefull information here soon